γδ T 细胞调节小细胞肺癌中的抗肿瘤免疫
γδ T cells modulate anti-tumor immunity in small cell lung cancer.
我们的发现表明,活化的γδ T细胞可能是SCLC治疗的有价值靶点。
英文原题:DLL3 serves as a pivotal hub bridging malignant progression and immunosuppression in NECC with therapeutic implications validated via the organoid-TIL co-culture system.
该研究为 NECC 的 TIME 以及超越传统治疗的 NECC 个体化治疗策略提供了全面见解。
宫颈神经内分泌癌(NECC)是侵袭性很强的宫颈癌亚型,其肿瘤免疫微环境(TIME)尚未得到充分表征,致癌机制也不明确。本研究通过单细胞 RNA 测序(scRNA-seq)发现,表达高水平 NECC 标志物(SYN/INSM1)的神经祖细胞(NPC)可能是恶性细胞,并沿其发育轨迹描绘出三种不同状态。值得注意的是,初始 T 细胞和耗竭 T 细胞均大量浸润,并共同塑造了免疫抑制性 TIME。细胞通讯分析发现,DLL3 可与 NPC 上的 NOTCH2 以及TIL(肿瘤浸润淋巴细胞)上的 NOTCH1/2 相互作用;多重免疫组化染色验证了其空间关系。功能实验显示 DLL3 可促进肿瘤细胞增殖和侵袭;共培养实验则表明,DLL3 会加重 T 细胞耗竭并损害 T 细胞激活。这些结果共同支持 DLL3 是协调恶性进展与免疫抑制的核心分子枢纽。免疫组化还证实 NECC 组织中 DLL3 表达升高且具有特异性,提示 DLL3 是 NECC 的潜在治疗靶点。研究还创新性地建立了 NECC 来源的类器官,能够重现亲本肿瘤的细胞形态、神经内分泌分化特征和遗传特征;并将类器官与TIL(肿瘤浸润淋巴细胞)共培养,以评估靶向 DLL3 的 AMG757 的治疗效果。值得注意的是,靶向 DLL3 的 AMG757 联合化疗(依托泊苷 + 顺铂)可诱导显著的 T 细胞聚集和激活,并增强免疫原性细胞死亡,为 NECC 治疗带来新的认识。总体而言,本研究深入揭示了 NECC 的 TIME,并提出了超越传统疗法的个体化治疗思路。
Neuroendocrine carcinoma of the cervix (NECC) represents a highly aggressive cervical cancer subtype with a poorly characterized tumor immune microenvironment (TIME) and unclear oncogenic mechanisms. Herein, through scRNA-seq analysis, we identified neuronal progenitor cells (NPCs) exhibiting high expression of NECC markers (SYN/INSM1) as putative malignant cells, and delineated three distinct NPC states along their developmental trajectory. Notably, we observed extensive infiltration of both na ve and exhausted T cells, collaboratively shaping an immunosuppressive TIME. Cellular communication analysis discovered DLL3's interaction with NOTCH2 on NPCs and NOTCH1/2 on tumor-infiltrating lymphocytes, with spatial relationships validated by multicolor immunohistochemistry staining. Functional experiments demonstrated that DLL3 promoted tumor cell proliferation and invasion, whereas co-culture assays revealed that DLL3 contributed to T cell exhaustion and impaired T cell activation, collectively proving DLL3 as a central molecular hub coordinating both malignant progression and immunosuppression. Moreover, we verified heightened and specific DLL3 expression in NECC tissues through immunohistochemistry staining, underscoring DLL3 as a promising therapeutic target for NECC. Significantly, we not only innovatively established NECC-derived organoids replicating cellular morphology, neuroendocrine differentiation features, and genetic characteristics of parental tumors, but also co-cultured organoids with tumor-infiltrating lymphocytes to assess the therapeutic efficacy of AMG757 targeting DLL3. Remarkably, the combination of AMG757 targeting DLL3 with chemotherapy (etoposide + cisplatin) induced substantial T cell aggregation and activation and heightened immunogenic cell death, offering novel insights into NECC treatment. Overall, the study provides comprehensive insights into NECC TIME and tailored therapeutic approaches beyond traditional therapy for NECC.
MEMBER ACCOUNT
登录成功会直接打开下一页。